{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:50Z","timestamp":1787026550399,"version":"build-2736575974"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI129703, R01 AI54559, R21 AI54559"],"award-info":[{"award-number":["AI129703, R01 AI54559, R21 AI54559"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51 OD011092"],"award-info":[{"award-number":["P51 OD011092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    CCR5 plays a central role in infectious disease, host defense, and cancer progression, thereby making it an ideal target for therapeutic development. Notably, CCR5 is the major HIV entry co-receptor, where its surface density correlates with HIV plasma viremia. The level of CCR5 receptor occupancy (RO) achieved by a CCR5-targeting therapeutic is therefore a critical predictor of its efficacy. However, current methods to measure CCR5 RO lack sensitivity, resulting in high background and overcalculation. Here, we report on two independent, flow cytometric methods of calculating CCR5 RO using the anti-CCR5 antibody, Leronlimab. We show that both methods led to comparable CCR5 RO values, with low background on untreated CCR5+CD4+ T cells and sensitive measurements of occupancy on both blood and tissue-resident CD4+ T cells that correlated longitudinally with plasma concentrations in Leronlimab-treated macaques. Using these assays, we found that Leronlimab stabilized cell surface CCR5, leading to an increase in the levels of circulating and tissue-resident CCR5+CD4+ T cells\n                    <jats:italic>in vivo<\/jats:italic>\n                    in Leronlimab-treated macaques. Weekly Leronlimab treatment in a chronically SIV-infected macaque led to increased CCR5+CD4+ T cells levels and fully suppressed plasma viremia, both concomitant with full CCR5 RO on peripheral blood CD4+ T cells, demonstrating that CCR5+CD4+ T cells were protected from viral replication by Leronlimab binding. Finally, we extended these results to Leronlimab-treated humans and found that weekly 700 mg Leronlimab led to complete CCR5 RO on peripheral blood CD4+ T cells and a statistically significant increase in CCR5+CD4+ T cells in peripheral blood. Collectively, these results establish two RO calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans, demonstrate that CCR5+CD4+ T cell levels temporarily increase with Leronlimab treatment, and facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.794638","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T02:53:18Z","timestamp":1637290398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiao L.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Tiwary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Waytashek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleiton","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Sylwester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Belica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Pourhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele M.","family":"Bochart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Smedley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Recknor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah B.","family":"Sacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"B1","article-title":"Cellular Localization of the Chemokine Receptor CCR5. Correlation to Cellular Targets of HIV-1 Infection","volume":"151","author":"Rottman","year":"1997","journal-title":"Am J Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01358","article-title":"The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection","volume":"8","author":"Venuti","year":"2017","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2000.108613","article-title":"Macrophages Infiltrating the Tissue in Chronic Pancreatitis Express the Chemokine Receptor CCR5","volume":"128","author":"Goecke","year":"2000","journal-title":"Surgery"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024364","article-title":"Paucity of CD4+CCR5+ T Cells is a Typical Feature of Natural SIV Hosts","volume":"109","author":"Pandrea","year":"2007","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12476","article-title":"Dengue Virus Requires the CC-Chemokine Receptor CCR5 for Replication and Infection Development","volume":"145","author":"Marques","year":"2015","journal-title":"Immunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature11724","article-title":"CCR5 Is a Receptor for Staphylococcus Aureus Leukotoxin ED","volume":"493","author":"Alonzo","year":"2013","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0915","article-title":"CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion","volume":"78","author":"Jiao","year":"2018","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030580","article-title":"CCR5 Expression Influences the Progression of Human Breast Cancer in a P53-Dependent Manner","volume":"198","author":"Manes","year":"2003","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1506","article-title":"CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1\/M2 Status","volume":"61","author":"Kitade","year":"2012","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.20985","article-title":"CCR5 Is a Suppressor for Cortical Plasticity and Hippocampal Learning and Memory","volume":"5","author":"Zhou","year":"2016","journal-title":"Elife"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.cell.2019.01.044","article-title":"CCR5 Is a Therapeutic Target for Recovery After Stroke and Traumatic Brain Injury","volume":"176","author":"Joy","year":"2019","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2020.11.037","article-title":"Insight Into the Roles of CCR5 in Learning and Memory in Normal and Disordered States","volume":"92","author":"Necula","year":"2021","journal-title":"Brain Behav Immun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)80110-5","article-title":"Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 Infection in Caucasian Individuals Bearing Mutant Alleles of the CCR-5 Chemokine Receptor Gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)03425-x","article-title":"Association of CCR5 Delta32 With Reduced Risk of Asthma","volume":"354","author":"Hall","year":"1999","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/02770900802386024","article-title":"Association of CCR5-Delta32 Mutation With Reduced Risk of Nonatopic Asthma in Slovenian Children","volume":"45","author":"Berce","year":"2008","journal-title":"J Asthma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.934647","article-title":"CCR5Delta32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects","volume":"70","author":"Hubacek","year":"2021","journal-title":"Physiol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364298","article-title":"Negative Association Between the Chemokine Receptor CCR5-Delta32 Polymorphism and Rheumatoid Arthritis: A Meta-Analysis","volume":"7","author":"Prahalad","year":"2006","journal-title":"Genes Immun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01897-06","article-title":"Genetic Protection Against Hepatitis B Virus Conferred by CCR5Delta32: Evidence That CCR5 Contributes to Viral Persistence","volume":"81","author":"Thio","year":"2007","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.504381","article-title":"Common CCR5-Del32 Frameshift Mutation Associated With Serum Levels of Inflammatory Markers and Cardiovascular Disease Risk in the Bruneck Population","volume":"39","author":"Afzal","year":"2008","journal-title":"Stroke"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363760","article-title":"Genetic Variation at the Chemokine Receptors CCR5\/CCR2 in Myocardial Infarction","volume":"2","author":"Gonzalez","year":"2001","journal-title":"Genes Immun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12974-015-0447-9","article-title":"CCR5 Limits Cortical Viral Loads During West Nile Virus Infection of the Central Nervous System","volume":"12","author":"Durrant","year":"2015","journal-title":"J Neuroinflamm"},{"key":"B24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12974-016-0656-x","article-title":"CCR5 Ameliorates Japanese Encephalitis via Dictating the Equilibrium of Regulatory CD4(+)Foxp3(+) T and IL-17(+)CD4(+) Th17 Cells","volume":"13","author":"Kim","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00134.2019","article-title":"ACKR2 Contributes to Pulmonary Dysfunction by Shaping CCL5:CCR5-Dependent Recruitment of Lymphocytes During Influenza A Infection in Mice","volume":"318","author":"Tavares","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65068-7","article-title":"Contrasting Effects of CCR5 and CCR2 Deficiency in the Pulmonary Inflammatory Response to Influenza A Virus","volume":"156","author":"Dawson","year":"2000","journal-title":"Am J Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1086\/314933","article-title":"CCR5 Delta32 Deletion and Reduced Risk of Toxoplasmosis in Persons Infected With Human Immunodeficiency Virus Type 1. The SEROCO-HEMOCO-SEROGEST Study Groups","volume":"180","author":"Meyer","year":"1999","journal-title":"J Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e104736","DOI":"10.1371\/journal.pone.0104736","article-title":"CCR5 Controls Immune and Metabolic Functions During Toxoplasma Gondii Infection","volume":"9","author":"Bonfa","year":"2014","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0016-5085(03)00903-x","article-title":"CCR5 Mediates Specific Migration of Toxoplasma Gondii-Primed CD8 Lymphocytes to Inflammatory Intestinal Epithelial Cells","volume":"125","author":"Luangsay","year":"2003","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102153440702","article-title":"Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients With Detectable Viremia","volume":"344","author":"Deeks","year":"2001","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340a239","article-title":"Rebound of Plasma Viremia Following Cessation of Antiretroviral Therapy Despite Profoundly Low Levels of HIV Reservoir: Implications for Eradication","volume":"24","author":"Chun","year":"2010","journal-title":"AIDS"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.9.1681","article-title":"CCR5 Levels and Expression Pattern Correlate With Infectability by Macrophage-Tropic HIV-1","volume":"185","author":"Wu","year":"1997","journal-title":"vitro J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1086\/315315","article-title":"CD4+ T Cell Surface CCR5 Density as a Determining Factor of Virus Load in Persons Infected With Human Immunodeficiency Virus Type 1","volume":"181","author":"Reynes","year":"2000","journal-title":"J Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.242134499","article-title":"Cell Surface CCR5 Density Determines the Postentry Efficiency of R5 HIV-1 Infection","volume":"99","author":"Lin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02555-07","article-title":"Paucity of CD4+ CCR5+ T Cells may Prevent Transmission of Simian Immunodeficiency Virus in Natural Nonhuman Primate Hosts by Breast-Feeding","volume":"82","author":"Pandrea","year":"2008","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nm1319","article-title":"Efficacy of Short-Term Monotherapy With Maraviroc, a New CCR5 Antagonist, in Patients Infected With HIV-1","volume":"11","author":"Fatkenheuer","year":"2005","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2125.2008.03140.x","article-title":"Population Pharmacokinetic\/Pharmacodynamic Analysis of CCR5 Receptor Occupancy by Maraviroc in Healthy Subjects and HIV-Positive Patients","author":"Rosario","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00576-18","article-title":"Marginal Effects of Systemic CCR5 Blockade With Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques","volume":"92","author":"Brocca-Cofano","year":"2018","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1038\/s41467-021-23697-6","article-title":"Antibody-Based CCR5 Blockade Protects Macaques From Mucosal SHIV Transmission","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1600-0684.2011.00521.x","article-title":"CCR5 Blockade is Well Tolerated and Induces Changes in the Tissue Distribution of CCR5+ and CD25+ T Cells in Healthy, SIV-Uninfected Rhesus Macaques","volume":"41","author":"Taaffe","year":"2012","journal-title":"J Med Primatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01204-13","article-title":"Lack of Prophylactic Efficacy of Oral Maraviroc in Macaques Despite High Drug Concentrations in Rectal Tissues","volume":"87","author":"Massud","year":"2013","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-735076","article-title":"Clinical and Immunologic Impact of CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis","volume":"129","author":"Moy","year":"2017","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2020.10.101","article-title":"CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14","volume":"103","author":"Patterson","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1086\/527327","article-title":"Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody Against CCR5, in HIV-1-Infected Patients","volume":"197","author":"Lalezari","year":"2008","journal-title":"J Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0684.2005.00128.x","article-title":"Highly Sensitive SIV Plasma Viral Load Assay: Practical Considerations, Realistic Performance Expectations, and Application to Reverse Engineering of Vaccines for AIDS","volume":"34","author":"Cline","year":"2005","journal-title":"J Med Primatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nature12519","article-title":"Immune Clearance of Highly Pathogenic SIV Infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.8.4134-4144.2004","article-title":"The Differential Sensitivity of Human and Rhesus Macaque CCR5 to Small-Molecule Inhibitors of Human Immunodeficiency Virus Type 1 Entry is Explained by a Single Amino Acid Difference and Suggests a Mechanism of Action for These Inhibitors","volume":"78","author":"Billick","year":"2004","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2019-0090","article-title":"Receptor Occupancy Measurement of Anti-PD-1 Antibody Drugs in Support of Clinical Trials","volume":"11","author":"Fu","year":"2019","journal-title":"Bioanalysis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s40425-019-0665-2","article-title":"Anti-PD-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies","volume":"7","author":"Naing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-436345","article-title":"The Immunologic Effects of Maraviroc Intensification in Treated HIV-Infected Individuals With Incomplete CD4+ T-Cell Recovery: A Randomized Trial","volume":"121","author":"Hunt","year":"2013","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1086\/652190","article-title":"Anti-HIV-1 Activity of Weekly or Biweekly Treatment With Subcutaneous PRO 140, a CCR5 Monoclonal Antibody","volume":"201","author":"Jacobson","year":"2010","journal-title":"J Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1086\/592169","article-title":"Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults","volume":"198","author":"Jacobson","year":"2008","journal-title":"J Infect Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a Monoclonal Antibody Targeting CCR5, as a Long-Acting, Single-Agent Maintenance Therapy for HIV-1 Infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin Trials"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-Term Control of HIV by CCR5 Delta32\/Delta32 Stem-Cell Transplantation","volume":"360","author":"Hutter","year":"2009","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 Remission Following CCR5\u039432\/\u039432 Haematopoietic Stem-Cell Transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1027","article-title":"Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases","volume":"161","author":"Henrich","year":"2014","journal-title":"Ann Internal Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144486","article-title":"CCR5-Edited CD4+ T Cells Augment HIV-Specific Immunity to Enable Post-Rebound Control of HIV Replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected With HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0612","article-title":"CCR5 Receptor Antagonists Block Metastasis to Bone of V-Src Oncogene-Transformed Metastatic Prostate Cancer Cell Lines","volume":"74","author":"Sicoli","year":"2014","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01391-1","article-title":"Leronlimab, a Humanized Monoclonal Antibody to CCR5, Blocks Breast Cancer Cellular Metastasis and Enhances Cell Death Induced by DNA Damaging Chemotherapy","volume":"23","author":"Jiao","year":"2021","journal-title":"Breast Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1583","article-title":"Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab","author":"Yang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100083","article-title":"Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated With Leronlimab","volume":"4","author":"Agresti","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2020.10.101","article-title":"CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14","volume":"103","author":"Patterson","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.041","article-title":"PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-Versus-Host Disease in NOD-Scid IL-2Ry(Null) Mice","volume":"24","author":"Burger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA Approves 100th Monoclonal Antibody Product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of Therapeutic Antibodies for the Treatment of Diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J BioMed Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.794638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T02:53:24Z","timestamp":1637290404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.794638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2021.794638"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.794638","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"article-number":"794638"}}